This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Children with recurrent or refractory solid tumor malignancies often have a poor prognosis. Finding a drug regimen that is successful in treating these children is paramount. the purpose of this study is to determine the maximum tolerated dose and to establish the dose limiting toxicities of a drug regimen called FOLFOX6 in pediatric patients with recurrent/refractory solid tumor malignancies. FOLFOX6 consists of a combination of the experimental drug Oxaliplatin along with the approved drugs Leucovorin and Fluorouracil.
Showing the most recent 10 out of 515 publications